{"id":"W2211107270","doi":"10.1200/jco.2009.27.15_suppl.5104","title":"A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Sorafenib; Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Dosing; Toxicity; Urology; Pazopanib; Progressive disease; Pharmacokinetics; Oncology; Gastroenterology; Hepatocellular carcinoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001915768,0.001411423,0.002655897,0.0005379359,0.0004965308,0.00105218,0.001388164,0.001183313,0.004571015],"category_scores_gemma":[0.0009489296,0.0007619522,0.001354601,0.0004788638,0.0009716497,0.0007447855,0.0004276702,0.003407012,0.001342166],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001243285,"about_ca_system_score_gemma":0.003189632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001632557,"about_ca_topic_score_gemma":0.003404719,"domain_scores_codex":[0.9993661,0.0002870333,0.00003570165,0.0001057974,0.00008144531,0.0001238499],"domain_scores_gemma":[0.9989514,0.0001491022,0.0001202967,0.00008390572,0.00005963122,0.0006356203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5885252,0.1839542,0.01041766,0.001357767,0.002239173,0.001058477,0.0006244014,0.004011533,0.1000268,0.0004799818,0.005850717,0.1014542],"study_design_scores_gemma":[0.4632093,0.5197974,0.008012469,0.00002498323,0.0003702856,0.0004798549,0.00005219855,0.001152576,0.004214318,0.0001143122,0.002545634,0.00002669325],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930171,0.001343146,0.0005974813,0.0003768319,0.0001219423,0.002853542,0.0005492109,0.00007685274,0.001064016],"genre_scores_gemma":[0.9863815,0.001675494,0.002457063,0.0006365256,0.0002013247,0.003355269,0.002608926,0.0000323731,0.002651734],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004571015,"threshold_uncertainty_score":0.01529157,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1727772208750895,"score_gpt":0.4757522930892986,"score_spread":0.3029750722142091,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}